Oncopeptides Valuation

Is ONCOS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ONCOS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ONCOS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ONCOS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ONCOS?

Key metric: As ONCOS barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ONCOS. This is calculated by dividing ONCOS's market cap by their current book value.
What is ONCOS's PB Ratio?
PB Ratio	4.1x
Book	SEK 228.42m
Market Cap	SEK 942.15m

ONCOS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	73.3x
Enterprise Value/EBITDA	-2x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does ONCOS's PB Ratio compare to its peers?

The above table shows the PB ratio for ONCOS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	41.3x
TRX Tissue Regenix Group	1.7x	170.8%	UK£40.6m
ETX e-therapeutics	1.9x	n/a	UK£52.6m
FARN Faron Pharmaceuticals Oy	145.3x	17.3%	UK£167.4m
BVXP Bioventix	16.3x	n/a	UK£195.7m
ONCOS Oncopeptides	4.1x	44.1%	SEK 942.1m

Price-To-Book vs Peers: ONCOS is expensive based on its Price-To-Book Ratio (4.1x) compared to the peer average (2.9x).

Price to Book Ratio vs Industry

How does ONCOS's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 Companies	Price / Book	Estimated Growth	Market Cap
DEST Destiny Pharma	0.3x	-15.5%	US$5.85m
BDRX Biodexa Pharmaceuticals	0.5x	n/a	US$4.42m
LLAI LungLife AI	0.4x	101.0%	US$3.46m
VAL ValiRx	0.6x	n/a	US$2.78m

No more companies available in this PB range

4 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: ONCOS is expensive based on its Price-To-Book Ratio (4.1x) compared to the UK Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is ONCOS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ONCOS PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	4.1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ONCOS's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.80

1.9%

12.1%

hVIVO

UK£134.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.20

-16.8%

2.1%

Regeneron Pharmaceuticals

US$80.6b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$750.19

0.5%

-5.7%